GemVax & KAEL reports further positive data from GV1001 Phase II Alzheimer’s Disease trial
GemVax & KAEL Co., Ltd.) a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association’s Fall Conference from a Phase II trial in Alzheimer’s disease of lead candidate GV1001. Previously the company announced GV1001 was well tolerated and safe and the primary […]
